Lexaria Bioscience engages advisory firm to identify new business opportunities

The company said, “For several years, Lexaria has been validating the applicability of its patented DehydraTECH technology across a number of sectors within the pharmaceutical industry. In parallel, Lexaria has pursued as many business opportunities as possible using historically limited internal resources, while acknowledging the early stages of DehydraTECH development for pharmaceutical applications. Lexaria’s R&D validation programs have already identified several pharmaceutical areas of interest including, but not limited to: treatments for diabetes control and weight loss, hypertension, seizure disorders, anti-viral applications and hormone replacement. Lexaria is pleased to announce it has now augmented its ongoing internally led business development activities by hiring a global life science business development advisory firm to help identify and pursue additional collaborative business opportunities around the world. Under the terms of that engagement, new outreach activities to the pharmaceutical and biotechnology sectors are underway. Due to the sensitive strategic nature of licensing and partnering discussions, details of the parties involved will remain confidential. The resources permitting this expansion of strategic outreach, and key supportive R&D related thereto, have been made available through Lexaria’s recently completed equity financing which yielded gross proceeds of $4.0 million on excellent terms. Prior to that financing, the Company’s existing operations and ongoing R&D programs were fully funded through the end of 2025. The additional capital was required in order to advance and execute plans for important supportive new R&D expansion activities into 2026. Most R&D projects require several months’ lead time for activities including study design, regulatory approvals, and entry into binding contracts with third-party vendors. With this in mind, had the Company not obtained these new funds, the first half of 2026 would have been devoid of vital new R&D programs and their attendant potential for corporate business development. Corporate finance decisions are thus an integral part of the Company’s broader strategic goals. R&D programs evolve hand-in-hand with building and strengthening business and strategic connections in the pharmaceutical and biotechnology industries. Even when successful collaboration agreements are reached, they are often limited in scope to narrowly defined areas of study and the short-term economic benefits to Lexaria might also be limited to those areas of mutual interest. However, because of its broad platform nature, Lexaria’s DehydraTECH technology has evidenced advantages and improvements in many different sectors and management believes the Company is now ready for the expanded outreach made possible through the engagement of the noted global life science business development firm. Empowered with new financial resources, Lexaria is now able to advance its business development and R&D programs through the winter and into the first half of calendar 2026. Once final decisions have been made and budgets have been established, the Company will provide additional updates on its exciting strategic R&D plans. During this period, we also anticipate the final results from the Company’s important Phase 1b Australian study in the GLP-1 sector, expected to evidence patient safety and efficacy with DehydraTECH processing of certain industry-leading GLP-1 and complementary drugs marketed today. In addition, Lexaria is pleased to announce that it has been awarded 4 new patents, continuing to build upon our already significant intellectual property portfolio. These patents support the immense value of our strategic R&D programs as they cover broad therapeutic applications within the fields of diabetes, hypertension, seizure disorders, antiviral treatments, and more.”